col blocks we are bridge builder col blocks
COVID Antworten in den wissenschaftlichen Zeitschriften der Welt


50 Ergebisse       Seite 1

 [1] 
Springer-Verlag: Pharmacological Reports
  Original Artikel Datum Titel Autoren   Alle Autoren
1 [GO] 2025―Apr―25 Post-marketing surveillance study on the effectiveness and safety of molnupiravir in high-risk COVID-19 outpatients: a prospective case series study Renato Ferreira-da-silva, Lurdes Silva, Cristina Costa-Santos, Manuela Morato, Jorge Junqueira Polónia, Inês Ribeiro-Vaz, et al. (+9)
2 [GO] 2025―Feb―03 Effects of COVID-19 and medication used for treatment and symptom prevention on the antioxidant status Laura A. Borba, Getúlio Antonio de Freitas Filho, Taiane de Azevedo Cardoso, Camila O. Arent, Flávia S. Niero, Lucas C. Pedro, et al. (+10)
3 [GO] 2024―Sep―19 JG26 attenuates ADAM17 metalloproteinase-mediated ACE2 receptor processing and SARS-CoV-2 infection in vitro Valentina Gentili, Silvia Beltrami, Doretta Cuffaro, Giorgia Cianci, Gloria Maini, Roberta Rizzo, et al. (+4)
4 [GO] 2024―Apr―23 Role of the RAAS in mediating the pathophysiology of COVID-19 Jakub Jasiczek, Adrian Doroszko, Tymoteusz Trocha, Małgorzata Trocha
5 [GO] 2024―Mrz―18 Effect of polyphenols against complications of COVID-19: current evidence and potential efficacy Mahdi Vajdi, Arash Karimi, Shirin Hassanizadeh, Mahdieh Abbasalizad Farhangi, Mohammad Bagherniya, Gholamreza Askari, et al. (+3)
6 [GO] 2023―Sep―01 Remdesivir and SARS-CoV-2 monoclonal antibodies to prevent COVID-19 progression in hematological patients: an observational study Juan Vicente-Valor, Carmen Rodríguez-González, María Ferris-Villanueva, Esther Chamorro-de-Vega, Rosa Romero-Jiménez, Daniel Gómez-Costas, et al. (+6)
7 [GO] 2023―Aug―16 Metabolomics-directed nanotechnology in viral diseases management: COVID-19 a case study Marwa O. El-Derany, Diana M. F. Hanna, John Youshia, Enas Elmowafy, Mohamed A. Farag, Samar S. Azab
8 [GO] 2023―Jun―24 Secondary fungal infections in SARS-CoV-2 patients: pathological whereabouts, cautionary measures, and steadfast treatments Raj Singh, Parth Malik, Mukesh Kumar, Raman Kumar, Md. Shamshir Alam, Tapan Kumar Mukherjee
9 [GO] 2023―Apr―05 Hospital antibiotic consumption-an interrupted time series analysis of the early and late phases of the COVID-19 pandemic in Poland, a retrospective study Małgorzata Siewierska, Mateusz Gajda, Aleksandra Opalska, Michał Brudło, Paweł Krzyściak, Barbara Gryglewska, et al. (+2)
10 [GO] 2023―Feb―27 Nasal sprays for treating COVID-19: a scientific note Vivek P. Chavda, Kajal P. Baviskar, Dixa A. Vaghela, Shilpa S. Raut, Anjali P. Bedse
11 [GO] 2022―Dez―04 Platelets in COVID-19 disease: friend, foe, or both? Marta Smęda, Ebrahim Hosseinzadeh Maleki, Agnieszka Pełesz, Stefan Chłopicki
12 [GO] 2022―Nov―18 Antiviral peptides against SARS-CoV-2: therapeutic targets, mechanistic antiviral activity, and efficient delivery Raahilah Zahir Essa, Yuan-seng Wu, Kalaivani Batumalaie, Mahendran Sekar, Chit-laa Poh
13 [GO] 2022―Nov―14 Health-related quality of life in survivors of severe COVID-19 infection Gabriele d’Ettorre, Paolo Vassalini, Vincenzo Coppolelli, Elio Gentilini Cacciola, Letizia Sanitinelli, Luca Maddaloni, et al. (+4)
14 [GO] 2022―Nov―07 Efficacy of COVID-19 vaccines: a systematic review and network meta-analysis of phase 3 randomized controlled trials Subodh Kumar, Dibyajyoti Saikia, Mangesh Bankar, Manoj Kumar Saurabh, Harminder Singh, Sheshadri Reddy Varikasuvu, Vikas Maharshi
15 [GO] 2022―Okt―10 Recent review of COVID-19 management: diagnosis, treatment and vaccination Vivek P. Chavda, Suneetha Vuppu, Toshika Mishra, Sathvika Kamaraj, Aayushi B. Patel, Nikita Sharma, Zhe-Sheng Chen
16 [GO] 2022―Okt―03 Correction: Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance Robert Flisiak, Dorota Zarębska-Michaluk, Magdalena Rogalska, Justyna Anna Kryńska, Justyna Kowalska, Ewa Dutkiewicz, et al. (+7)
17 [GO] 2022―Sep―30 Neurological consequences of COVID-19 Waldemar Brola, Maciej Wilski
18 [GO] 2022―Sep―27 Short-chain fatty acids-microbiota crosstalk in the coronavirus disease (COVID-19) Jakub Włodarczyk, Bartłomiej Czerwiński, Jakub Fichna
19 [GO] 2022―Sep―23 Correction: Oral antiviral treatments for COVID-19: opportunities and challenges Laila Rahmah, Sunny O. Abarikwu, Amanuel Godana Arero, Mickael Essouma, Aliyu Tijani Jibril, Andrzej Fal, et al. (+8)
20 [GO] 2022―Sep―20 Plant-derived immuno-adjuvants in vaccines formulation: a promising avenue for improving vaccines efficacy against SARS-CoV-2 virus Arbind Kumar, Aashish Sharma, Narendra Vijay Tirpude, Yogendra Padwad, Vipin Hallan, Sanjay Kumar
21 [GO] 2022―Aug―24 Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance Robert Flisiak, Dorota Zarębska-Michaluk, Magdalena Rogalska, Justyna Anna Kryńska, Justyna Kowalska, Ewa Dutkiewicz, et al. (+7)
22 [GO] 2022―Aug―23 Effects of L-carnitine supplementation in patients with mild-to-moderate COVID-19 disease: a pilot study Seyed Saman Talebi, Mehran Ghasemi, Maryam Etminani-Esfahani, Younes Mohammadi, Rasool Haddadi
23 [GO] 2022―Aug―23 The roles of cellular protease interactions in viral infections and programmed cell death: a lesson learned from the SARS-CoV-2 outbreak and COVID-19 pandemic Martyna Majchrzak, Marcin Poręba
24 [GO] 2022―Aug―05 Jacareubin inhibits TLR4-induced lung inflammatory response caused by the RBD domain of SARS-CoV-2 Spike protein Deisy Segura-Villalobos, Daniela Roa-Velázquez, Dan I. Zavala-Vargas, Jessica G. Filisola-Villaseñor, Jorge Ivan Castillo Arellano, Edgar Morales Ríos, et al. (+2)
25 [GO] 2022―Jul―25 Oral antiviral treatments for COVID-19: opportunities and challenges Laila Rahmah, Sunny O. Abarikwu, Amanuel Godana Arero, Aliyu Tijani Jibril, Andrzej Fal, Robert Flisiak, et al. (+7)
26 [GO] 2022―Mrz―23 To aspirate or not to aspirate? Considerations for the COVID-19 vaccines Piotr Rzymski, Andrzej Fal
27 [GO] 2022―Jan―15 A perspective on the applications of furin inhibitors for the treatment of SARS-CoV-2 Kasi Pandima Devi, Mahmoud Reza Pourkarim, Marijn Thijssen, Antoni Sureda, Maryam Khayatkashani, Cosmin Andrei Cismaru, et al. (+4)
28 [GO] 2021―Nov―27 Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial Negar Toroghi, Ladan Abbasian, Anahid Nourian, Effat Davoudi-Monfared, Hossein Khalili, Malihe Hasannezhad, et al. (+4)
29 [GO] 2021―Aug―30 COVID-19: potential therapeutics for pediatric patients Nour K. Younis, Rana O. Zareef, Ghina Fakhri, Fadi Bitar, Ali H. Eid, Mariam Arabi
30 [GO] 2021―Jul―06 The application of in silico experimental model in the assessment of ciprofloxacin and levofloxacin interaction with main SARS-CoV-2 targets: S-, E- and TMPRSS2 proteins, RNA-dependent RNA polymerase and papain-like protease (PLpro)-preliminary molecular docking analysis Krzysztof Marciniec, Artur Beberok, Stanisław Boryczka, Dorota Wrześniok
31 [GO] 2021―Jun―27 Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: a potential approach for therapeutic intervention Ekta Shirbhate, Jaiprakash Pandey, Vijay K. Patel, Mehnaz Kamal, Talha Jawaid, Bapi Gorain, et al. (+2)
32 [GO] 2021―Jun―24 Novel adenosine derivatives against SARS-CoV-2 RNA-dependent RNA polymerase: an in silico perspective Amr Sonousi, Hanan A. Mahran, Ibrahim M. Ibrahim, Mohamed N. Ibrahim, Abdo A. Elfiky, Wael M. Elshemey
33 [GO] 2021―Jun―04 Use of glucocorticoids and azithromycin in the therapy of COVID-19 Miguel de Lemos Neto, Rafael Costa Vieira Alexandre, Rafaela Oliveira Gallart Morra, Juliana Aparecida Souza da Paz, Shana Priscila Coutinho Barroso, Angela Castro Resende, et al. (+2)
34 [GO] 2021―Mai―10 Rifampicin and Letermovir as potential repurposed drug candidate for COVID-19 treatment: insights from an in-silico study Yamini Pathak, Amaresh Mishra, Gourav Choudhir, Anuj Kumar, Vishwas Tripathi
35 [GO] 2021―Apr―21 Role of pirfenidone in TGF-β pathways and other inflammatory pathways in acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection: a theoretical perspective Seyed Hootan Hamidi, Sandhya Kadamboor Veethil, Seyedeh Harir Hamidi
36 [GO] 2021―Apr―11 Proton pump inhibitor on susceptibility to COVID-19 and its severity: a systematic review and meta-analysis Raymond Pranata, Ian Huang, Sherly Lawrensia, Joshua Henrina, Michael Anthonius Lim, Antonia Anna Lukito, et al. (+2)
37 [GO] 2021―Mrz―29 The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis Chia Siang Kow, Hamid A. Merchant, Zia Ul Mustafa, Syed Shahzad Hasan
38 [GO] 2021―Mrz―05 Perspectives on glucocorticoid treatment for COVID-19: a systematic review Leonardo P. Cordeiro, Eduarda O. N. N. Linhares, Fernanda G. O. Nogueira, Daniel Moreira-Silva, Daniel J. M. Medeiros-Lima
39 [GO] 2021―Feb―24 Evaluation of effects of chronic nasal steroid use on rhinological symptoms of COVID-19 with SNOT-22 questionnaire Akif İşlek, Mustafa Koray Balcı
40 [GO] 2021―Feb―20 In-hospital use of statins is associated with a reduced risk of mortality in coronavirus-2019 (COVID-19): systematic review and meta-analysis Hikmat Permana, Ian Huang, Aga Purwiga, Nuraini Yasmin Kusumawardhani, Teddy Arnold Sihite, Erwan Martanto, et al. (+2)
41 [GO] 2021―Feb―19 Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2 Albert Cortés-Borra, Gonzalo Emiliano Aranda-Abreu
42 [GO] 2021―Jan―03 Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes Harpinder Kaur, Nishant Shekhar, Saurabh Sharma, Phulen Sarma, Ajay Prakash, Bikash Medhi
43 [GO] 2021―Jan―03 SARS-CoV-2 therapeutics: how far do we stand from a remedy? Anurag Singh, Vandana Gupta
44 [GO] 2020―Nov―09 The effect of tocilizumab on cytokine release syndrome in COVID-19 patients Carmen de Cáceres, Rodrigo Martínez, Pablo Bachiller, Laura Marín, José Manuel García
45 [GO] 2020―Okt―28 Overview of the possible role of vitamin C in management of COVID-19 Anis Abobaker, Aboubaker Alzwi, Alsalheen Hamed A. Alraied
46 [GO] 2020―Okt―15 Ciprofloxacin and moxifloxacin could interact with SARS-CoV-2 protease: preliminary in silico analysis Krzysztof Marciniec, Artur Beberok, Paweł Pęcak, Stanisław Boryczka, Dorota Wrześniok
47 [GO] 2020―Okt―10 Observational study of people infected with SARS-Cov-2, treated with amantadine Gonzalo Emiliano Aranda-Abreu, José D. Aranda-Martínez, Ramiro Araújo, María Elena Hernández-Aguilar, Deissy Herrera-Covarrubias, Fausto Rojas-Durán
48 [GO] 2020―Sep―05 Drug repurposing approach to fight COVID-19 Thakur Uttam Singh, Subhashree Parida, Madhu Cholenahalli Lingaraju, Manickam Kesavan, Dinesh Kumar, Raj Kumar Singh
49 [GO] 2020―Aug―20 Pharmacological treatments of COVID-19 Adeleh Sahebnasagh, Razieh Avan, Fatemeh Saghafi, Mojataba Mojtahedzadeh, Afsaneh Sadremomtaz, Omid Arasteh, et al. (+8)
50 [GO] 2020―Jul―22 Cepharanthine: a review of the antiviral potential of a Japanese-approved alopecia drug in COVID-19 Moshe Rogosnitzky, Paul Okediji, Igor Koman
 [1] 

50 Ergebisse       Seite 1


[de][en]

Letzte Änderung 2023―Okt―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.005 sec